It is well known that primary and secondary glioblastomas are histologically largely indistinguishable. Therefore, the detection of IDRI mutations or the status of the MGMT p.romoter on a simple bioptic sample could be one of major diagnostic and prognostic importance for glial patients that complements clinical criteria for distinguishing secondary from primary glioblastomas and to predict a more favorable prognosis. Currently, biopsy is the method of choice to obtain tissue from intracranial lesions with uncertain neurodiagnostic findings or in deep locations, with a minimal invasive approach. The needle biopsy with frameless neuronavigation could provide a sampling with elevated diagnostic yield and high concentration of DNA, due to the "image-guided" computer assisted technique of needle insertion through the most neurodiagnostic representative tumoral area. The freezing of fresh tumor tissue at biopsy could greatly improve the success of DNA extraction. The concentration ofthe DNA samples can also improved from a withdrawal in an area with high probability of neoplastic cells. The present study reports the results of 17 patients who had undergone frameless image-guided intracranial needle biopsy from April 2008 until July 2010 at Neurosurgery Unit of the "Arcispedale Santa Maria Nuova" of Reggio Emilia. For these patients the molecular determination of MGMT promoter was assessed with the Nested-Methylation Specific-Polymerase Chain Reaction and the screening of mutations in IDRI e IDR2 genes was performer by polymerase chain reaction (PCR) and direct sequencing on fresh or cryopreserved needle bioptic tissue.
Presently, there are limited treatment options for glioma; glioblastoma, the most common glioma subtype, remains an incurable disease with a median survival of 15 months, even with radiation and temozolomide therapy (1). A patient may not be entered in recent chemotherapy protocols without a histopathological or molecular genetic analysis (2) .
The most widely studied epigenetic mark is DNA methylation that occurs at cytosine residues in the context of CpG dinucleotides. The 06-methylguanine DNA methyltransferase (MGMT) promoter methylation has recently been recognized as the most powerful determinant of chemotherapy sensitivity in patients with glioblastomas (3) Since 2008, sequencing of gliomas has identified mutations in the isocitrate dehydrogenase I and 2 (IDRI and IDR2) genes. Patients with IDRI mutated glioblastoma multiform have a better prognosis that those without IDRI mutations, with respect to both overall survival (OS) and progression-free survival (4, 5) . IDRI appears to have a native function as a tumor suppressor that, when mutational inactivated, contributes to tumorigenesis in part through induction of the HIF-l pathway (6) .
The accuracy of the frameless neuronavigation needle biopsy is assessed in previous studies (7) , allowing an "image-guided" withdrawal with a selection ofthe optimal target for histopathological and genetic characterization.
MATERIALS AND METHODS
The present study reports the results of 17 patients who had undergone frameless image-guided intracranial needle biopsy from April 2008 until July 2010 at Neurosurgery Unit of the "Arcispedale Santa Maria Nuova" of Reggio Emilia. The mean age of the seventeen investigated patients was 60.6 years (±13.4 years SD) and the study cohort consisted of8 male and 9 female patients (Table I) The neuroimaging protocol for neuronavigation included at least contrast-enhanced l-mm slices Computed Tomography (CT) or Magnetic Resonance Imaging (MRl) (pre-and postcontrast isotropic Tl-weighted and FLAIR/T2-weighted MRl sequences for the non-enhancing lesions).
Automatic surface merging program was used to enable operating room neuronavigational registration. The surgical plan, and thus the entry point, biopsy target and needle trajectory, were determined pre-operatively and performed using the iNav™ neuronavigation portable station and the Stealthstation® S7™ neuronavigation station (Medtronic Inc., Minneapolis, MN,USA). A Sedan/Nashold side-cutting needle was introduced through a burr hole fixation needle trajectory guide, after dura opening.
The sampling protocol included first withdrawals of fresh tissue sent in saline solution. One sample for intra-operative freeze-sectioning histopathological analysis, and another sample for genetic characterization in the molecular biology laboratory. Another sample was fixed in formaline and sent to the pathologist to be successively paraffin embedded for a definitive histopathological analysis. All the withdrawals are performed always under optic guidance system control, to keep the sample site in the lesional zone with the neuronavigator (Fig.  1,2 ). The bioptic procedure is concluded after intra-operative freeze-sectioning histopathological confirmed the tumoral aspect of the withdrawals.
The fresh tissue samples obtained from intraoperative withdrawals were in part used for a cytological smear analysis and in part were frozen for histological examination. The samples obtained at surgery were fixed in 10% buffered formalin and embedded in paraffin for histopathological and immunoistochemical study. Section were stained by Haematoxylin-Eosin ( Fig. 2 c,d ). Immunohistochemical staining was performed using the peroxidise-antiperoxidase technique. The following monoclonal and polyclonal primary antibodies were utilized: glial fibrillary acidic protein (GFAP; Dako, clone 6F2, dilution 1:200), S100 protein (S 100; Dako, polyclonal, dilution 1:800), KI67 (KI67; Dako, clone Mib-I ,dilution 1:200), P53 (P53; Dako, clone DO-7, dilution 1:100). Microwave pretreatment was performed with all antibodies.
Genomic DNA was extracted from patient samples using a fast spin-column procedure (QIAGEN Hilden Germany).
The concentration and the quality of the DNA samples was performed in a spectrophotometer, various amount ofDNA (500 ng -I J.1g) were converted using sodium bisulphite treatment using a commercial kit (QIAGEN Hilden Germany) shows over 99% conversion ofunmethylated cytosine. According with Shen et al. (8) , we performed MSP (Methylation Specific Polymerase Chain Reaction) using the following oligonucleotide primers: sense 5'-GTAGGTTGTTTGTATGTTTGT-3' and antisense 5'-AACCAATACAAACCAAACA-3' for amplification of unmethylated DNA that produced a Polymerase Chain Reaction (PCR)productsizeofl21 bpand5'-GGTCGTTTGTACGTTCGC-3' and 5'-GACCGATACAAACCGAACG-3 ' for amplification of methylated DNA with a PCR product size of 118 bp. Methylated and unmethylated amplifications had the same PCR cycle conditions: 95°C for 2 minutes, followed by 40 cycles of 95 "C for 20 seconds, 60°C for 20 seconds, and 72 "C for 20 seconds, and finally, 72 "C for 3 minutes. If the results are too weak, IJ.11 of the first product was amplified again with the same conditions. MSP provides qualitative data, and a sample was called positive for methylation if a band was seen in a 2.5% agarose gel stained with ethidium bromide in DNA amplified by the methylated reaction primers. In two methylated and two unmethylated samples, we confirm the MGMT promoter CpG state, using DNA sequencing (Beckman Coulter CEQ2000XL) after bisulphite treatment. The screening of mutations in IDH I e IDH2 genes was performed by polymerase chain reaction (PCR) and direct sequencing. Exon 4 ofIDHI and IDH2 was amplified from genomic DNA extract from fresh biopsy, using AmpliTaq (Applied Biosystems, Forster City, CA,USA) and the specific primers: IDHl-FOR (5'-TGCCACCAACGACCAAGTCA-3'), IDHl-REV (5'-CATGCAAAATCACATATTTGCC-3'), IDH2-FOR (5'-TGAAAGATGGCGGCTGCAGT-3') and IDH2-REV (5'-GGGGTGAAGACCATTTTGAA-3'). The PCR product were directly sequenced using GenomeLab DTCS Quick Start Kit (Beckman Coulter) and analyzed using CEQ 8000 Genetic Analysis System (Beckman Coulter).
RESULTS
The hystopathologic, genetic and clinical results are summarized in Table I .
Pathologic tissue was found in 100% of bioptic samples. The comparison of histopathological data and imaging features resulted in a very high correlation (Fig.  1,2 ).
The histological diagnosis shows eleven Glioblastoma (GBL) (WHO grade IV), three Anaplastic Astrocytomas (AA) (WHO Grade III), two Diffuse Astrocytoma (DA) (WHO grade II) and one Low Grade Glioma (LGG) (WHO grade II).
The genetic characterization was feasible in all the bioptic samples. From the analysis of MGMT promoter methylation status performed on the fresh needle bioptic tissue six GBL (54.5%), two AA and one DA showed a methylated MGMT promoter, while the LGG, one DA, one AA and five GBL, were not methylated. The IDH mutation was found in 4 cases: in two AA and one GBL (LGG) . The analysis ofthe status ofthe MGMTpromoter showed a methylation in 6111 GEL, in 213 AA, in 112 DA and in Oil LGG The IDH mutation was found in 4 cases: in 2 AA and 1 GEL resulted a arginine to histidine (R132H) substitution in IDHl, and in 1 AA resulted an arginine to lysine (RI72K) substitution in IDH2. The global overall survive (OS) was 7.5 months (±6.6 months SD). The mean OS ofthe three low grade gliomas (LGGandDA) was 15.7 months, while in the high grade gliomas group (AA and GEL) the 8 patients with methylation ofthe MGMTpromoter showed an OS 0/6.8 months (AVG), respect to OS of4.2 month (AVG) ofthe unmethylated promoter ofMGMT group. 5 high grade gliomas still alives. All but one showed methylation ofthe MGMTpromoter and/or IDH1 mutation, with a follow-up from 6 to 1~,!,onths. resulted a argmme to histidine (R132H) substitution in IDHI, and in one AA resulted an arginine to lysine (RinK) substitution in IDH2 (Table I) .
The OS of the seventeen patiens was 7.5 month (±6.6 months SD). The mean OS of the three low grade gliomas (WHO II grade) was 15.7, while in the high grade gliomas group the patients with methylation ofthe MGMT promoter showed an OS of 6.8 months (AVG), respect to OS of 4.2 month (AVG) of the unmethylated promoter of MGMT group. All 5 high grade gliomas still alive but one showed methylation of the MGMT promoter and/or IDHI mutation, with a follow-up from 6 to 13 months.
Four patients died less than 3 month after biopsy, the other patients were managed with adjuvant therapies (Radiation therapy and/or chemotherapy). All the patients was ineligible for surgery due to deep location, multicentric aspect of the gliomas, corpus callosum involvement, diffuse infiltration, refuse of operation by the patient, WHO Grade II.
DISCUSSION
In the present report, the biopsies performed with a frameless neuronavigation system introducing a Sedan! Nashold side-cutting needle through a burr hole fixation needle trajectory guide apparatus to obtain a sample with an elevated concentration of DNA. The accuracy of the frameless neuronavigation, is assessed in previous studies (9) . The combination of an adjustable locking tool and neuronavigation equipment provides both accurate interactive localization and rigid instrument guidance with an high correlation comparing histopathological data and imaging features. (Fig. 1,2) . The entry point, the trajectory, and the target can be visualized on reconstructed images in various planes, during the surgicalprocedure. In 2008 Kuhn et at. (10) in a series of thirteen stereotactic frame-based neuronavigation biopsy demonstrates a high correlation between the imaging features and tumor morphology with the aid of the intraoperative mobile CT gantry. With the frameless needle biopsy the selection of the optimal target for histopathological and genetic characterization can be recognized and achieved on the most probably tumoral area on the neurodiagnostic imaging, with an elevated concentration of neoplastic DNA (Fig.2) . The MSP assay requires only small quantities of DNA and can be performed on DNA extracted from paraffin-embedded tissue samples; however, fixation may cause deterioration of the DNA. Therefore, best results are obtained with cryopreserved tumor specimens (3) . The screening of mutations in IDHI e IDH2 genes was performer by peR and direct sequencing on fresh or cryopreserved needle bioptic tissue, to confirm how elevated concentration of DNA could be found in the fresh tissue from neuronavigated biopsy.
Major advances in the clinical role of epigenetic in gliomas include the findings that MGMT promoter gene is the most powerful determinant of temozolomide treatment sensitivity in patients with glioblastomas (11) . Patients with IDH mutation have significantly improved survival as reported in previous work (5) . The IDHI mutation is common in almost all glioma subtypes and in younger patients, ranging from 50% to 80%, respect to about 5% in primary GBM. IDHI is among the few genes that are commonly mutated in grade II and grade III gliomas (12) . The prevalence of IDHI mutation in secondary GBM can distinguish between primary and secondary GBM (sensitivity 71 . 0-73%, specificity 96%). The low incidence of IDHI mutation in pilocytic astrocytomas also allows clinically relevant differentiation between diffuse and pilocytic astrocytomas (sensitivity 73-83%, specificity 100%) (13) . IDH2 mutations are much less First withdrawal at the outer area ofa non-enhancing lesion at MR!. The intra-operative freeze-sectioning histopathological showed gliotic tissue. The second withdrwal is performedfew millimetres deeper in the hyperdense region oftumor on FLAIRlT2-weighted MRJ sequences, under "image-guided" control at the neuronavigator monitor. The intra-operative freeze-sectioning histopathological confirmed the tumoral aspect ofthe withdrawals. common than IDHI mutations and are associated with oligodendrogliomas (14) . IDHI mutations are rarely seen in pilocytic astrocytomas, which are circumscript (nondiffuse) grade I gliomas (15) .
It is well known that primary and secondary glioblastomas are histologically largely indistinguishable Therefore, the detection of IDHI mutations or the status of the MGMT promoter on a simple bioptic sample could be one of major diagnostic and prognostic importance for glial patients that complements clinical criteria for distinguishing secondary from primary glioblastomas and to predict a more favorable prognosis. The eight patients with high-grade gliomas and methylation of the MGMT promoter showed an as of6.8 months (AVG), respect to the 4.2 month (AVG) ofthe six patients with unmethylated MGMT promoter high grade glioma. Among 5 high grade gliomas still alive patients, four showed methylation ofthe MGMT promoter and/or IDHI mutation, with a follow-up from 6 to 13 months.
The GBL patient of the present series with IDHI R132H mutation showed an as of 9.7 months compared to 5.7 months of the GBL/AA group and to 4.2 months of the not methylated MGMT promoter group, where the patient was included. Presence of IDHI mutations in AA and oligodendroglial tumors was shown to be associated with a significantly better outcome (16) . In the presented series, among three cases with AA the only still alive patient after thirteen months from biopsy showed a IDHI R132H mutation. Interestingly, those few primary GBL with IDHI mutations also have a significantly better prognosis (17) . Houillier et al. (18) report IDH mutation appears to be a significant marker ofpositive prognosis and chemosensitivity in low-grade gliomas too, whereas its impact on the course of untreated tumors seems to be limited. Unfortunately, the patient of the present study with DA (WHO grade II) and IDHI mutation, died after 6.1 months due to intratumoral hematoma, during observational follow-up. Much attention has recently been given to the utility of MGMT methylation in predicting response to therapy. The major prognostic importance ofIDHl mutation status suggests that it should be used as a stratification factor in controlled clinical trials.
The detection of IDHI mutations or the status of the MGMT promoter on a simple bioptic sample could be one of major diagnostic and prognostic importance for glial patients, that complements clinical criteria for distinguishing secondary from primary glioblastomas and to predict a more favorable prognosis including the ineligible patients for craniotomy and tumor resection.
